{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:23:18Z","timestamp":1789827798184,"version":"4.0.1"},"reference-count":119,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"vor","delay-in-days":376,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100022332","name":"ACT for Alexandria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022332","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.medj.2024.04.008","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T10:41:15Z","timestamp":1715683275000},"page":"689-717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Reverse repurposing: Potential utility of cancer drugs in nonmalignant illnesses"],"prefix":"10.1016","volume":"5","author":[{"given":"Mina","family":"Nikanjam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumei","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob J.","family":"Adashek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanna","family":"Block","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2024.04.008_bib1","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1158\/2159-8290.CD-18-1321","article-title":"Targeting Alterations in the RAF-MEK Pathway","volume":"9","author":"Yaeger","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.medj.2024.04.008_bib2","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The Frequency of Ras Mutations in Cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2024.04.008_bib3","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1056\/NEJMoa1709449","article-title":"Somatic Activating KRAS Mutations in Arteriovenous Malformations of the Brain","volume":"378","author":"Nikolaev","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.04.008_bib4","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/jamadermatol.2018.4653","article-title":"Genotype-Guided Medical Treatment of an Arteriovenous Malformation in a Child","volume":"155","author":"Lekwuttikarn","year":"2019","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.medj.2024.04.008_bib5","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/pde.14912","article-title":"Successful management of an arteriovenous malformation with trametinib in a patient with capillary-malformation arteriovenous malformation syndrome and cardiac compromise","volume":"39","author":"Nicholson","year":"2022","journal-title":"Pediatr. Dermatol."},{"key":"10.1016\/j.medj.2024.04.008_bib6","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/jamaoncol.2016.0891","article-title":"Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors","volume":"2","author":"Millis","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.medj.2024.04.008_bib7","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.medj.2024.04.008_bib8","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41586-018-0217-9","article-title":"Targeted therapy in patients with PIK3CA-related overgrowth syndrome","volume":"558","author":"Venot","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.medj.2024.04.008_bib9","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.molmed.2018.08.003","article-title":"Cancer-Associated PIK3CA Mutations in Overgrowth Disorders","volume":"24","author":"Madsen","year":"2018","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.medj.2024.04.008_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1158\/1078-0432.CCR-23-1270","article-title":"FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum","volume":"30","author":"Singh","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2024.04.008_bib11","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1177\/1947601911408889","article-title":"Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis","volume":"2","author":"Rivlin","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.medj.2024.04.008_bib12","first-page":"932","article-title":"Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53","volume":"62","author":"Angelo","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2024.04.008_bib13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","article-title":"IL-6 in inflammation, autoimmunity and cancer","volume":"33","author":"Hirano","year":"2021","journal-title":"Int. Immunol."},{"key":"10.1016\/j.medj.2024.04.008_bib14","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.3390\/ijms17121975","article-title":"The Double Role of p53 in Cancer and Autoimmunity and Its Potential as Therapeutic Target","volume":"17","author":"Fierabracci","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.medj.2024.04.008_bib15","doi-asserted-by":"crossref","first-page":"10895","DOI":"10.1073\/pnas.94.20.10895","article-title":"Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium","volume":"94","author":"Firestein","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.medj.2024.04.008_bib16","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/698313","article-title":"Interleukin 6 and rheumatoid arthritis","volume":"2014","author":"Yoshida","year":"2014","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.medj.2024.04.008_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw036","article-title":"The Conundrum of Genetic \"Drivers\" in Benign Conditions","volume":"108","author":"Kato","year":"2016","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.medj.2024.04.008_bib18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13073-020-0714-y","article-title":"The paradox of cancer genes in non-malignant conditions: implications for precision medicine","volume":"12","author":"Adashek","year":"2020","journal-title":"Genome Med."},{"key":"10.1016\/j.medj.2024.04.008_bib19","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41416-023-02502-9","article-title":"Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy","volume":"130","author":"Weth","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.medj.2024.04.008_bib20","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.semcancer.2020.01.008","article-title":"Repurposing drugs in oncology: From candidate selection to clinical adoption","volume":"68","author":"Pantziarka","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.medj.2024.04.008_bib21","unstructured":"Vanderbilt-Ingram Cancer Center. My Cancer Genome. https:\/\/www.mycancergenome.org\/content\/biomarkers\/."},{"key":"10.1016\/j.medj.2024.04.008_bib22","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR Project GENIE: Powering Precision Medicine through an International Consortium","volume":"7","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.medj.2024.04.008_bib23","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ajhg.2019.01.015","article-title":"Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome","volume":"104","author":"Keppler-Noreuil","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.medj.2024.04.008_bib24","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jid.2015.12.023","article-title":"Sustained Akt Activity Is Required to Maintain Cell Viability in Seborrheic Keratosis, a Benign Epithelial Tumor","volume":"136","author":"Neel","year":"2016","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.medj.2024.04.008_bib25","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s11864-023-01144-6","article-title":"Update of Diagnosis and Targeted Therapy for ALK+ Inflammation Myofibroblastic Tumor","volume":"24","author":"Wang","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.medj.2024.04.008_bib26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41698-023-00449-x","article-title":"ALK fusions in the pan-cancer setting: another tumor-agnostic target?","volume":"7","author":"Shreenivas","year":"2023","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.medj.2024.04.008_bib27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ctrv.2017.11.002","article-title":"Targeting the Wnt\/beta-catenin pathway in cancer: Update on effectors and inhibitors","volume":"62","author":"Krishnamurthy","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.medj.2024.04.008_bib28","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00431-023-05263-y","article-title":"Novel therapeutic perspectives in Noonan syndrome and RASopathies","author":"Saint-Laurent","year":"2023","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.medj.2024.04.008_bib29","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.3390\/genes14122111","article-title":"The Cardiofaciocutaneous Syndrome: From Genetics to Prognostic-Therapeutic Implications","volume":"14","author":"Scorrano","year":"2023","journal-title":"Genes"},{"key":"10.1016\/j.medj.2024.04.008_bib30","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12916-024-03293-3","article-title":"Neuregulin-1 and ALS19 (ERBB4): at the crossroads of amyotrophic lateral sclerosis and cancer","volume":"22","author":"Adashek","year":"2024","journal-title":"BMC Med."},{"key":"10.1016\/j.medj.2024.04.008_bib31","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/jmedgenet-2013-101603","article-title":"FGFR1 mutations cause Hartsfield syndrome, the unique association of holoprosencephaly and ectrodactyly","volume":"50","author":"Simonis","year":"2013","journal-title":"J.\u00a0Med. Genet."},{"key":"10.1016\/j.medj.2024.04.008_bib32","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.168796","article-title":"Hypochondroplasia gain-of-function mutation in FGFR3 causes defective bone mineralization in mice","volume":"8","author":"Loisay","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.medj.2024.04.008_bib33","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221084848","article-title":"Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies","volume":"14","author":"Savarirayan","year":"2022","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.medj.2024.04.008_bib34","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1159\/000477562","article-title":"Clinical Benefit from Trametinib in a Patient with Appendiceal Adenocarcinoma with a GNAS R201H Mutation","volume":"10","author":"Ang","year":"2017","journal-title":"Case Rep. Oncol."},{"key":"10.1016\/j.medj.2024.04.008_bib35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1399-0004.2007.00743.x","article-title":"HRAS and the Costello syndrome","volume":"71","author":"Rauen","year":"2007","journal-title":"Clin. Genet."},{"key":"10.1016\/j.medj.2024.04.008_bib36","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/s41591-023-02382-9","article-title":"Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation","volume":"29","author":"Geoerger","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2024.04.008_bib37","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1210\/clinem\/dgac045","article-title":"It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease","volume":"107","author":"Girnita","year":"2022","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.medj.2024.04.008_bib38","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1158\/1078-0432.CCR-09-3220","article-title":"A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors","volume":"16","author":"Kurzrock","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2024.04.008_bib39","doi-asserted-by":"crossref","first-page":"10031","DOI":"10.1200\/jco.2011.29.15_suppl.10031","article-title":"Cixutumumab combined with temsirolimus in patients with refractory Ewing\u2019s sarcoma","volume":"29","author":"Naing","year":"2011","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2024.04.008_bib40","doi-asserted-by":"crossref","first-page":"463","DOI":"10.18632\/oncotarget.886","article-title":"A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R): implications for inhibition of the IGF-1R signal","volume":"4","author":"Janku","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.medj.2024.04.008_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.887168","article-title":"Identification of Immune Hub Genes Associated With Braak Stages in Alzheimer's Disease and Their Correlation of Immune Infiltration","volume":"14","author":"Qian","year":"2022","journal-title":"Front. Aging Neurosci."},{"issue":"Suppl 1","key":"10.1016\/j.medj.2024.04.008_bib42","first-page":"A243","article-title":"LB-002 Liquid biopsy identifies somatic KRAS mutations in paediatric cranio-spinal arterio-venous malformations: preliminary results","volume":"14","author":"Bhatia","year":"2023","journal-title":"J.\u00a0of Neurointerv. Surg."},{"key":"10.1016\/j.medj.2024.04.008_bib43","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/hmg\/ddac169","article-title":"Trametinib as a promising therapeutic option in alleviating vascular defects in an endothelial KRAS-induced mouse model","volume":"32","author":"Nguyen","year":"2023","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.medj.2024.04.008_bib44","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.jacc.2019.01.066","article-title":"Hypertrophic Cardiomyopathy in Noonan Syndrome Treated by MEK-Inhibition","volume":"73","author":"Andelfinger","year":"2019","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.medj.2024.04.008_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2022.104630","article-title":"Succesful MEK-inhibition of severe hypertrophic cardiomyopathy in RIT1-related Noonan Syndrome","volume":"65","author":"Leegaard","year":"2022","journal-title":"Eur. J. Med. Genet."},{"key":"10.1016\/j.medj.2024.04.008_bib46","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jpeds.2022.05.030","article-title":"Trametinib for Refractory Chylous Effusions and Systemic Complications in Children with Noonan Syndrome","volume":"248","author":"Nakano","year":"2022","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.medj.2024.04.008_bib47","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.bbrc.2020.06.022","article-title":"Endothelial MAP2K1 mutations in arteriovenous malformation activate the RAS\/MAPK pathway","volume":"529","author":"Smits","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.medj.2024.04.008_bib48","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3390\/ph15080956","article-title":"Efficacy and Safety of Trametinib in Neurofibromatosis Type 1-Associated Plexiform Neurofibroma and Low-Grade Glioma: A Systematic Review and Meta-Analysis","volume":"15","author":"Wang","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.medj.2024.04.008_bib49","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1200\/JCO.2011.38.2614","article-title":"Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside","volume":"30","author":"Subbiah","year":"2012","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2024.04.008_bib50","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1128\/MCB.01581-08","article-title":"NF2\/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth","volume":"29","author":"James","year":"2009","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.medj.2024.04.008_bib51","doi-asserted-by":"crossref","first-page":"67","DOI":"10.18632\/oncotarget.1557","article-title":"NF2\/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations","volume":"5","author":"Schroeder","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.medj.2024.04.008_bib52","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.jid.2019.03.1156","article-title":"Local Inhibition of MEK\/Akt Prevents Cellular Growth in Human Congenital Melanocytic Nevi","volume":"139","author":"Rouille","year":"2019","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.medj.2024.04.008_bib53","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.jid.2019.04.009","article-title":"Can Combination MEK and Akt Inhibition Slay the Giant Congenital Nevus?","volume":"139","author":"Murphy","year":"2019","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.medj.2024.04.008_bib54","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-2469","article-title":"Giant Congenital Melanocytic Nevus Treated With Trametinib","volume":"143","author":"Mir","year":"2019","journal-title":"Pediatrics"},{"key":"10.1016\/j.medj.2024.04.008_bib55","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.det.2016.07.001","article-title":"Mosaic Disorders of the PI3K\/PTEN\/AKT\/TSC\/mTORC1 Signaling Pathway","volume":"35","author":"Nathan","year":"2017","journal-title":"Dermatol. Clin."},{"key":"10.1016\/j.medj.2024.04.008_bib56","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1093\/hmg\/ddac111","article-title":"A randomized controlled trial of everolimus for neurocognitive symptoms in PTEN hamartoma tumor syndrome","volume":"31","author":"Srivastava","year":"2022","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.medj.2024.04.008_bib57","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12876-015-0397-9","article-title":"Clinical characteristics and STK11 gene mutations in Chinese children with Peutz-Jeghers syndrome","volume":"15","author":"Huang","year":"2015","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.medj.2024.04.008_bib58","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1200\/JCO.2010.32.7825","article-title":"mTOR inhibitor treatment of pancreatic cancer in a patient with Peutz-Jeghers syndrome","volume":"29","author":"Klumpen","year":"2011","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2024.04.008_bib59","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1158\/0008-5472.CAN-14-2305","article-title":"VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy","volume":"75","author":"Schwaederle","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2024.04.008_bib60","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1158\/1078-0432.CCR-06-2416","article-title":"Vascular endothelial growth factor and its relationship to inflammatory mediators","volume":"13","author":"Angelo","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2024.04.008_bib61","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1158\/1535-7163.MCT-16-0196","article-title":"TP53 Alterations Correlate with Response to VEGF\/VEGFR Inhibitors: Implications for Targeted Therapeutics","volume":"15","author":"Wheler","year":"2016","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.medj.2024.04.008_bib62","doi-asserted-by":"crossref","first-page":"5238","DOI":"10.3390\/ijms21155238","article-title":"Interleukin-6 in Rheumatoid Arthritis","volume":"21","author":"Pandolfi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.medj.2024.04.008_bib63","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1158\/1078-0432.CCR-12-3349","article-title":"A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease","volume":"19","author":"Kurzrock","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2024.04.008_bib64","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.humimm.2019.03.003","article-title":"B cells in chronic graft-versus-host disease","volume":"80","author":"McManigle","year":"2019","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.medj.2024.04.008_bib65","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.intimp.2008.10.004","article-title":"A review of the current use of rituximab in autoimmune diseases","volume":"9","author":"Gurcan","year":"2009","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.medj.2024.04.008_bib66","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"45","author":"Wollin","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.medj.2024.04.008_bib67","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/1535-7163.MCT-22-0323","article-title":"JAK: Not Just Another Kinase","volume":"21","author":"Agashe","year":"2022","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.medj.2024.04.008_bib68","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/neuonc\/noac165","article-title":"MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus","volume":"24","author":"de Blank","year":"2022","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.medj.2024.04.008_bib69","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2024.04.008_bib70","series-title":"xPharm: The Comprehensive Pharmacology Reference","first-page":"1","article-title":"Everolimus","author":"Beljanski","year":"2008"},{"key":"10.1016\/j.medj.2024.04.008_bib71","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.gendis.2019.09.015","article-title":"An updated review on activated PI3 kinase delta syndrome (APDS)","volume":"7","author":"Singh","year":"2020","journal-title":"Genes Dis"},{"key":"10.1016\/j.medj.2024.04.008_bib72","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2021.05.010","article-title":"RAF-MEK-ERK pathway in cancer evolution and treatment","volume":"85","author":"Ullah","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.medj.2024.04.008_bib73","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1158\/1535-7163.MCT-15-0643","article-title":"Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm","volume":"15","author":"Turski","year":"2016","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.medj.2024.04.008_bib74","article-title":"Expanding the Benefit: Dabrafenib\/Trametinib as Tissue-Agnostic Therapy for BRAF V600E-Positive Adult and Pediatric Solid Tumors","volume":"43","author":"Gouda","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.medj.2024.04.008_bib75","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.medj.2024.04.008_bib76","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ng1054","article-title":"High frequency of BRAF mutations in nevi","volume":"33","author":"Pollock","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.medj.2024.04.008_bib77","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1001\/jamadermatol.2014.838","article-title":"Involution of eruptive melanocytic nevi on combination BRAF and MEK inhibitor therapy","volume":"150","author":"Chen","year":"2014","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.medj.2024.04.008_bib78","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/jid.2013.531","article-title":"Hiding in plain sight: molecular genetics applied to giant congenital melanocytic nevi","volume":"134","author":"Etchevers","year":"2014","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.medj.2024.04.008_bib79","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.049107","article-title":"The RASopathies: from pathogenetics to therapeutics","volume":"15","author":"Hebron","year":"2022","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.medj.2024.04.008_bib80","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.annonc.2020.03.291","article-title":"Germline and sporadic cancers driven by the RAS pathway: parallels and contrasts","volume":"31","author":"Dunnett-Kane","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.medj.2024.04.008_bib81","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1614814","article-title":"Cancer-Associated Mutations in Endometriosis without Cancer","volume":"376","author":"Anglesio","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.04.008_bib82","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/humupd\/dmv060","article-title":"Kinase signalling pathways in endometriosis: potential targets for non-hormonal therapeutics","volume":"22","author":"McKinnon","year":"2016","journal-title":"Hum. Reprod. Update"},{"key":"10.1016\/j.medj.2024.04.008_bib83","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1038\/s41467-019-11000-7","article-title":"Brain somatic mutations observed in Alzheimer's disease associated with aging and dysregulation of tau phosphorylation","volume":"10","author":"Park","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.medj.2024.04.008_bib84","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1158\/1078-0432.CCR-20-5032","article-title":"FDA Approval Summary: Selumetinib for Plexiform Neurofibroma","volume":"27","author":"Casey","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2024.04.008_bib85","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/s41591-019-0479-2","article-title":"ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor","volume":"25","author":"Li","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2024.04.008_bib86","article-title":"Tuberous sclerosis complex","volume":"2","author":"Henske","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.medj.2024.04.008_bib87","series-title":"FDA approves everolimus for tuberous sclerosis complex-associated partial-onset seizures","year":"2018"},{"key":"10.1016\/j.medj.2024.04.008_bib88","series-title":"StatPearls","article-title":"Peutz-Jeghers Syndrome","author":"Wu","year":"2024"},{"key":"10.1016\/j.medj.2024.04.008_bib89","series-title":"GeneReviews","article-title":"Proteus Syndrome","author":"Biesecker","year":"1993"},{"key":"10.1016\/j.medj.2024.04.008_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2023.100969","article-title":"Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS)","volume":"25","author":"Canaud","year":"2023","journal-title":"Genet. Med."},{"key":"10.1016\/j.medj.2024.04.008_bib91","first-page":"342","article-title":"FDA approves PI3K inhibitor for a rare immune disorder","volume":"22","author":"Mullard","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.medj.2024.04.008_bib92","doi-asserted-by":"crossref","first-page":"13450","DOI":"10.1073\/pnas.0705218104","article-title":"Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern","volume":"104","author":"Hafner","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.medj.2024.04.008_bib93","series-title":"DermBiont Announces Positive Phase 2 Clinical Trial Data Treating Seborrheic Keratosis with SM-020, the First and Only Targeted Topical Treatment for these Common Benign Tumors","year":"2022"},{"key":"10.1016\/j.medj.2024.04.008_bib94","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","article-title":"Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance","volume":"124","author":"Krook","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.medj.2024.04.008_bib95","series-title":"StatPearls","article-title":"Pfeiffer Syndrome","author":"Das","year":"2024"},{"key":"10.1016\/j.medj.2024.04.008_bib96","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000492266","article-title":"Genetic Causes of Craniosynostosis: An Update","volume":"10","author":"Goos","year":"2019","journal-title":"Mol. Syndromol."},{"key":"10.1016\/j.medj.2024.04.008_bib97","series-title":"GeneReviews","article-title":"Muenke Syndrome","author":"Kruszka","year":"1993"},{"key":"10.1016\/j.medj.2024.04.008_bib98","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/sj.ejhg.5200883","article-title":"Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders","volume":"10","author":"van Rhijn","year":"2002","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.medj.2024.04.008_bib99","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-77345-y","article-title":"Evaluation of FGFR inhibitor ASP5878 as a drug candidate for achondroplasia","volume":"10","author":"Ozaki","year":"2020","journal-title":"Sci. Rep."},{"issue":"Suppl 1","key":"10.1016\/j.medj.2024.04.008_bib100","article-title":"OR27-03 Oral Infigratinib Treatment Is Well Tolerated And Significantly Increases Height Velocity In Children With Achondroplasia: Month 6 Results From The PROPEL 2 Dose-finding Study","volume":"7","author":"Savarirayan","year":"2023","journal-title":"J.\u00a0Endocr. Soc"},{"key":"10.1016\/j.medj.2024.04.008_bib101","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1158\/1078-0432.CCR-19-0160","article-title":"Detection of NRG1 Gene Fusions in Solid Tumors","volume":"25","author":"Jonna","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2024.04.008_bib102","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.medj.2024.04.008_bib103","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/lymphatics2010002","article-title":"A Review of Anti-CD20 Antibodies in the Management of B-Cell Lymphomas","volume":"2","author":"Mahadevia","year":"2024","journal-title":"Lymphatics"},{"key":"10.1016\/j.medj.2024.04.008_bib104","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1080\/21645515.2018.1508624","article-title":"Anti-CD20 monoclonal antibodies: reviewing a revolution","volume":"14","author":"Casan","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.medj.2024.04.008_bib105","series-title":"FDA Approves First Treatment for Group of Progressive Interstitial Lung Diseases","year":"2020"},{"key":"10.1016\/j.medj.2024.04.008_bib106","doi-asserted-by":"crossref","DOI":"10.1177\/1753466618800618","article-title":"Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience","volume":"12","author":"Rivera-Ortega","year":"2018","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.medj.2024.04.008_bib107","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1056\/NEJMc2312807","article-title":"Adjuvant Alpelisib Therapy for Congenital Hyperinsulinism","volume":"390","author":"Dauleh","year":"2024","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.04.008_bib108","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3390\/cancers15030703","article-title":"Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy","volume":"15","author":"Sirico","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.medj.2024.04.008_bib109","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K Pathway in Human Disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.medj.2024.04.008_bib110","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41573-021-00209-1","article-title":"PI3K inhibitors are finally coming of age","volume":"20","author":"Vanhaesebroeck","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.medj.2024.04.008_bib111","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/ph16040614","article-title":"Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics","volume":"16","author":"Tateo","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.medj.2024.04.008_bib112","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.trecan.2020.05.009","article-title":"Clinical Development of BRAF plus MEK Inhibitor Combinations","volume":"6","author":"Subbiah","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.medj.2024.04.008_bib113","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40364-021-00281-0","article-title":"MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions","volume":"9","author":"Harder","year":"2021","journal-title":"Biomark. Res."},{"key":"10.1016\/j.medj.2024.04.008_bib114","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1634\/theoncologist.2010-0212","article-title":"Castleman's disease: from basic mechanisms to molecular therapeutics","volume":"16","author":"El-Osta","year":"2011","journal-title":"Oncol."},{"key":"10.1016\/j.medj.2024.04.008_bib115","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/17512433.2022.2097905","article-title":"Current status and prospects of IL-6-targeting therapy","volume":"15","author":"Narazaki","year":"2022","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.medj.2024.04.008_bib116","doi-asserted-by":"crossref","first-page":"5295","DOI":"10.3390\/molecules27165295","article-title":"Overview of Research into mTOR Inhibitors","volume":"27","author":"Mao","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.medj.2024.04.008_bib117","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12943-023-01929-1","article-title":"JAK\/STAT in leukemia: a clinical update","volume":"23","author":"Liang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.medj.2024.04.008_bib118","series-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","article-title":"Gonadotropin Releasing Hormone (GnRH) Analogues","year":"2012"},{"key":"10.1016\/j.medj.2024.04.008_bib119","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.3390\/cancers15123199","article-title":"Repurposing of Chronically Used Drugs in Cancer Therapy: A Chance to Grasp","volume":"15","author":"Hijazi","year":"2023","journal-title":"Cancers"}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024001788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024001788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:00:02Z","timestamp":1762639202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634024001788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":119,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2666634024001788"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2024.04.008","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reverse repurposing: Potential utility of cancer drugs in nonmalignant illnesses","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2024.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}